Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)

Health Policy

Volumn 119, Issue 2, 2015, Pages 156-163

  Chambers, James D ^a,b   Cangelosi, Michael J ^a,b   Neumann, Peter J ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Cost effectiveness; Evidentiary standards; Medicare; Prevention

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAMMOGRAPHY; MEDICAL SOCIETY; MEDICARE; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; ALCOHOLISM; COST BENEFIT ANALYSIS; ECONOMICS; HIV INFECTIONS; ORGANIZATION AND MANAGEMENT; PREVENTIVE MEDICINE; UNITED STATES;

ALCOHOLISM; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MEDICARE; PREVENTIVE MEDICINE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84922761554     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2014.11.012     Document Type: Article

References (76)

1. Department of Health NHS 2010-2015: from good to great. Preventative, people-centred, productive 2009, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/228885/7775.pdf [accessed 01.10.14].
2. Australian National Preventive Health Agency (ANPHA) State of preventive health 2013. Report to the Australian Government Minister for Health 2013, ANPHA, Canberra, http://www.anpha.gov.au/internet/anpha/publishing.nsf/Content/state-of-prev-health-2013 [accessed 01.10.14].
3. European Society of Lifestyle Medicine and Organization of American College of Preventive Medicine American and European medical societies devoted to prevention and healthy lifestyles announce partnership 2014, http://c.ymcdn.com/sites/www.acpm.org/resource/resmgr/PressReleases/pr_ESLM&ACPMPartnership.pdf [accessed 01.10.14].
4. Patient Protection and Affordable Care Act, Pub L No. 111-148, 124 Stat 119; 2010.
5. Davis K., Stremikis K., Squires D., Schoen C. Mirror, mirror on the wall 2014 update: how the U.S. health care system compares internationally 2014, http://www.commonwealthfund.org/publications/fund-reports/2014/jun/mirror-mirror [accessed 01.10.14].
6. Social Security Act, Pub L No. 74-271, 49 Stat 620; 1935.
7. Davis K., Bialek R., Parkinson M., Smith J., Vellozzi C. Paying for preventive care: moving the debate forward. American Journal of Preventive Medicine 1990, 6(Suppl. 4):7-30.
8. Federal Register Notice: Medicare program; revised process for making Medicare national coverage determinations, Federal Register 68, no 187 2003.
9. Chambers J.D., Morris S., Neumann P.J., Buxton M.J. Factors predicting Medicare national coverage: an empirical analysis. Medical Care 2012, 50(March (3)):249-256.
10. Chambers J.D., Neumann P.J., Buxton M.J. Does Medicare have an implicit cost-effectiveness threshold?. Medical Decision Making 2010, 30(July (4)):E14-E27.
11. Neumann P.J., Kamae M.S., Palmer J.A. Medicare's national coverage decisions for technologies, 1999-2007. Health Affairs 2008, 27(November (6)):1620-1631.
12. Neumann P.J., Divi N., Beinfeld M.T., Levine B.S., Keenan P.S., Halpern E.F., et al. Medicare's national coverage decisions, 1999-2003: quality of evidence and review times. Health Affairs 2005, 24(January (1)):243-254.
13. Act to amend title XVIII of the Social Security Act to provide for Medicare coverage of pneumococcal vaccine and its administration. Pub L. No. 96-611, 94 Stat 3566; 1980.
14. Schauffler H.H. Disease prevention policy under Medicare: a historical and political analysis. American Journal of Preventive Medicine 1993, 9(March (2)):71-77.
15. Catastrophic Coverage Repeal Act of 1989. H.R. 3607 (101st); 1989.
16. American Public Health Association Medicare to cover mammograms under the New Budget Law. The Nations Health 1990, February(20):2. [Report No.: 2].
17. Faust H.S., Menzel P.T. Prevention vs. treatment: what's the right balance? 2012, Oxford University Press, New York.
18. Centers for Medicare & Medicaid Services Decision memo for smoking & tobacco use cessation counseling (CAG-00241N) 2005, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=130&ver=16&NcaName=Smoking+%26+Tobacco+Use+Cessation+Counseling&DocID=CAG-00241N&bc=gAAAABAAEAAA&&fromdb=true [accessed 01.10.14].
19. Centers for Medicare & Medicaid Services Decision memo for screening for human immunodeficiency virus (HIV) infection (CAG-00409N) 2009, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=229&IsPopup=y&NCDId=335&NcaName=Screening+for+the+Human+Immunodeficiency+Virus+%28HIV%29+Infection&ncdver=1&bc=AAAAAAAACAAAAA%3D%3D& [accessed 01.10.14].
20. Centers for Medicare & Medicaid Services Decision memo for screening for depression in adults (CAG-00425N) 2011, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=251 [accessed 01.10.14].
21. Centers for Medicare & Medicaid Services Decision memo for screening and behavioral counseling interventions in primary care to reduce alcohol misuse (CAG-00427N) 2011, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=249&ver=5&NcaName=Screening+and+Behavioral+Counseling+Interventions+in+Primary+Care+to+Reduce+Alcohol+Misuse&DocID=CAG-00427N&bc=gAAAAAgAIBAA& [accessed 01.10.14].
22. Centers for Medicare & Medicaid Services Decision memo for intensive behavioral therapy for cardiovascular disease (CAG-00424N) 2011, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=248&fromdb=true [accessed 01.10.14].
23. Centers for Medicare & Medicaid Services Decision memo for intensive behavioral therapy for obesity (CAG-00423N) 2011, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=253&ver=4&NcaName=Intensive+Behavioral+Therapy+for+Obesity&DocID=CAG-00423N&from2=search.asp&bc=gAAAAAgAIAAA& [accessed 01.10.14].
24. Centers for Medicare & Medicaid Services Decision memo for screening for sexually transmitted infections (STIs) and high-intensity behavioral counseling (HIBC) to prevent STIs (CAG-00426N) 2011, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=250 [accessed 01.10.14].
25. Neumann P.J., Chambers J.D. Medicare's enduring struggle to define "reasonable and necessary" care. New England Journal of Medicine 2012, 367(November (19)):1775-1777.
26. Eddy D.M. Oregon's plan. Should it be approved?. JAMA 1991, 266(November (17)):2439-2445.
27. Neumann P.J. Using cost-effectiveness analysis to improve health care: opportunities and barriers 2005, Oxford University Press, USA.
28. Centers for Medicare & Medicaid Services Decision memo for autologous cellular immunotherapy treatment of metastatic prostate cancer (CAG-00422N) 2011, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=247&ver=12&NcaName=Autologous+Cellular+Immunotherapy+Treatment+of+Metastatic+Prostate+Cancer&TimeFrame=7&DocType=All&bc=AgAAYAAAIAAA& [accessed 01.10.14].
29. Holko P., Kawalec P. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Review of Anticancer Therapy 2014, 14(January (1)):63-73.
30. Food and Drug Administration FDA news release - FDA Commissioner announces Avastin decision - drug not shown to be safe and effective in breast cancer patients 2011, http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm280536.htm [accessed 01.10.14].
31. Chambers J.D., Lord J., Cohen J.T., Neumann P.J., Buxton M.J. Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures. Value Health 2013, 16(June (4)):629-638.
32. Ramsey S.D., Sullivan S.D. Evidence, economics, and emphysema: Medicare's long journey with lung volume reduction surgery. Health Affairs 2005, 24(January (1)):55-66.
33. Office of Technology Assessment Update of federal activities regarding the use of pneumococcal vaccine 1984, http://www.princeton.edu/~ota/disk3/1984/8432/843201.PDF [accessed 01.10.14].
34. Congressional Quarterly Service Congress and the nation: a review of government and politics. Congression Quarterly 1982, 5(1977-1980 (7-11)):601-653.
35. Office of Technology Assessment Breast cancer screening for Medicare beneficiaries: effectiveness, costs to Medicare, and medical resources required 1987, U.S. Government Printing Office, Washington, DC, http://catalog.hathitrust.org/Record/002976847 [accessed 01.10.14].
36. Office of Technology Assessment The costs and effectiveness of cervical cancer screening in elderly women 1990, U.S. Government Printing Office, Washington, DC.
37. Office of Technology Assessment Costs and effectiveness of colorectal cancer screening in the elderly 1990, U.S. Government Printing Office, Washington, DC.
38. Office of Technology Assessment Screening for open-angle glaucoma in the elderly 1988, U.S. Government Printing Office, Washington, DC.
39. Office of Technology Assessment Costs and effectiveness of cholesterol screening in the elderly 1989, U.S. Government Printing Office, Washington, DC.
40. Omnibus Budget Reconciliation Act of 1987. Pub L No. 100-203, 101 Stat 1330; 1987.
41. Gross C.P., Andersen M.S., Krumholz H.M., McAvay G.J., Proctor D., Tinetti M.E. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. Journal of the American Medical Association 2006, 296(December (23)):2815-2822.
42. Balanced Budget Act of 1997. Pub L No. 105-33, 111 Stat 251; 1997.
43. Centers for Medicare & Medicaid Services Decision memo for Screening Computed Tomography Colonography (CTC) for Colorectal Cancer (CAG-00396N) 2009, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=220&ver=14&NcaName=Screening+Computed+Tomography+Colonography+%28CTC%29+for+Colorectal+Cancer&bc=BEAAAAAAEAAA&&fromdb=true [accessed 01.10.14].
44. Medicare Improvements for Patients and Providers Act of 2008. Pub L No. 110-275, 122 Stat. 2494; 2008.
45. Hope T. Rationing and life-saving treatments: should identifiable patients have higher priority?. Journal of Medical Ethics 2001, 27(June (3)):179-185.
46. Jenni K.E., Loewenstein G. Explaining the "Identifiable Victim Effect". Journal of Risk and Uncertainty 1997, 14(3):235-257.
47. Esserman L.J., Thompson I.M., Reid B., Nelson P., Ransohoff D.F., Welch H.G., et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. The Lancet Oncology 2014, 15(May (6)):e234-e242.
48. Welch H.G., Schwartz L., Woloshin S. Overdiagnosed: making people sick in the pursuit of health 2012, Beacon Press, Boston, MA. 1st ed.
49. Welch H.G. Screening mammography - a long run for a short slide?. New England Journal of Medicine 2010, 363(September (13)):1276-1278.
50. Cohen J.T., Neumann P.J., Weinstein M.C. Does preventive care save money? Health economics and the presidential candidates. New England Journal of Medicine 2008, 358(February (7)):661-663.
51. Russell L.B. Preventing chronic disease: an important investment, but don't count on cost savings. Health Affairs 2009, 28(January (1)):42-45.
52. Chambers J.D., Neumann P.J. Listening to Provenge - what a costly cancer treatment says about future Medicare policy. New England Journal of Medicine 2011, 364(May (18)):1687-1689.
53. Fox J. The hidden role of cost: Medicare decisions, transparency and public trust. The University of Cincinnati Law Review 2010, 79(1):1-51.
54. Centers for Medicare & Medicaid Services Decision memo for screening DNA stool test for colorectal cancer (CAG-00144N) 2008, http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=212&NcaName=Screening+DNA+Stool+Test+for+Colorectal+Cancer&NCDId=281&ncdver=2&IsPopup=y&bc=AAAAAAAACAAAAA%3D%3D& [accessed 01.10.14].
55. Patient Centered Outcomes Research Institute. 2013. [accessed 01.10.14]. http://www.pcori.org/.
56. Neumann P.J., Weinstein M.C. Legislating against use of cost-effectiveness information. The New England Journal of Medicine 2010, 363(October (16)):1495-1497.
57. Selby J. Straight talk with...Joe Selby. Nature Medicine 2012, 18(August (8)):1164.
58. Chambers J.D. Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?. Pharmacoeconomics 2014, 32(August (8)):729-733.
59. Caremark C.V.S. Formulary drug exclusions 2014 2013, http://www.cmu.edu/hr/benefits/benefit_programs/forms/Formulary-Drug-Removals.pdf [accessed 01.10.14].
60. Express Scripts 2014 drugs not covered 2013, https://member.express-scripts.com/images/pdf/refdrugexclusionlist.pdf[(accessed 01.10.14].
61. The American College of Cardiology and the American Heart Association (AHA). ACC/AHA to include cost/value assessments in guidelines and performance measures 2014, http://www.Cardiosource.org/News-Media/Publications/Cardiology-Magazine/2014/03/ACCAHA-to-Include-CostValue-Assessments-in-Guidelines-and-Performance-Measures.aspx [accessed 01.10.14].
62. American Society of Clinical Oncology ASCO in action brief: value in cancer care 2014, http://www.asco.org/advocacy/asco-action-brief-value-cancer-care [accessed 01.10.14].
63. American Board of Internal Medicine Choosing wisely campaign 2013, http://www.choosingwisely.org/ [accessed 01.10.14].
64. Washington State Health Care Authority Washington State Health Care Authority Health Technology Assessment Program 2013, http://www.hca.wa.gov/hta/Pages/index.aspx [accessed 01.10.14].
65. Department of Defense The Department of Defense (DoD) PharmacoEconomic Center (PEC) 2013, http://www.pec.ha.osd.mil/ [accessed 01.10.14].
66. Wellpoint Wellpoint health technology assessment guidelines. Drug submission guidelines for re-evaluation of products, indications, and formulations 2008, National Pharmacy and Therapeutics Committee, http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12236 [accessed 01.10.14].
67. Botta M.D., Blendon R.J., Benson J.M. Cost-effectiveness decision making and US public opinion. JAMA Internal Medicine 2014, 174(January (1)):141-143.
68. Chambers J.D., Weiner D.E., Bliss S.K., Neumann P.J. What can we learn from the U.S. expanded end-stage renal disease bundle?. Health Policy 2013, February(110):164-171.
69. U.S.Congress Office of Technology Assessment A review of selected federal vaccine and immunization policies, based on case studies of pneumococcal vaccine 1979, US Government Printing Office, Washington, DC, https://www.princeton.edu/~ota/disk3/1979/7915/7915.PDF [accessed 01.10.14].
70. U.S.Centers for Disease Control Final results: Medicare influenza vaccine demonstration - selected states, 1988-1992. Morbidity and Mortality Weekly Report (MMWR) 1993, 42(31):601-604.
71. Institute of Medicine The role of nutrition in maintaining health in the nation's elderly: evaluating coverage of nutrition services for the Medicare population. Institute of Medicine 2000, http://www.nap.edu/catalog.php?record_id=9741 [accessed 01.10.14].
72. Solberg L.I., Maciosek M.V., Edwards N.M., Khanchandani H.S., Goodman M.J. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. American Journal of Preventive Medicine 2006, 31(July (1)):62-71.
73. Sanders G.D., Bayoumi A.M., Holodniy M., Owens D.K. Cost-effectiveness of HIV screening in patients older than 55 years of age. Annals of Internal Medicine 2008, 148(June (12)):889-903.
74. Simon G.E., Katon W.J., Lin E.H., Rutter C., Manning W.G., Von Korff M., et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Archives of General Psychiatry 2007, 64(January (1)):65-72.
75. Solberg L.I., Maciosek M.V., Edwards N.M. Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness. American Journal of Preventive Medicine 2008, 34(February (2)):143-152.
76. Schalm S.W., Mazel J.A., de Gast G.C., Heijtink R.A., Botman M.J., Bänffer J.R., et al. Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics 1989, 83(June (6)):1041-1048.